Healthcare Sales & Marketing Network News: Atopic Dermatitis

Searching News Database: Atopic Dermatitis

HSMN NewsFeed - 17 Jun 2026
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 12 Dec 2025
Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline
Biopharmaceuticals Dermatology Venture Capital

HSMN NewsFeed - 25 Aug 2025
Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4R?) for Atopic Dermatitis Achieve Primary Endpoints
Biopharmaceuticals

HSMN NewsFeed - 10 Feb 2025
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 31 Oct 2024
Evommune Announces $115 Million Series C Financing to Accelerate Advancement of Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 25 Oct 2024
Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab
Biopharmaceuticals Dermatology

HSMN NewsFeed - 14 Jun 2024
TALVEY(R) (talquetamab-tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Apr 2024
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Dec 2023
Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Apr 2023
Evommune Closes $50 Million Series B Financing to Advance Broad Pipeline of Therapies to Treat Chronic Inflammatory Diseases
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 23 Dec 2022
Hyphens Pharma Licenses Winlevi(R) for All 10 ASEAN countries from Cosmo Pharmaceuticals
Biopharmaceuticals Dermatology Licensing

HSMN NewsFeed - 18 Oct 2022
Dr. Brett King Joins BiologicsMD as Senior Scientific Advisor and Member of the Scientific Advisory Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Sep 2022
Alphyn Biologics Closes $3.3 Million Series A Financing to Advance Breakthrough Atopic Dermatitis Treatment
Biopharmaceuticals Dermatology Venture Capital

HSMN NewsFeed - 22 Aug 2022
Biosion, Inc. Appoints Steven Knapp, Pharm.D. as Chief Regulatory & Quality Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Aug 2022
Amgen to Acquire Chemocentryx for $4 Billion in Cash
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 7 Jun 2022
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
Biopharmaceuticals Dermatology

HSMN NewsFeed - 21 Dec 2021
Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study
Biopharmaceuticals Dermatology

HSMN NewsFeed - 20 Oct 2021
FDA Expands Approval of Dupixent(R) (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Sep 2021
OLUMIANT(R) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
Biopharmaceuticals

HSMN NewsFeed - 24 Aug 2021
European Commission Approves RINVOQ(R) (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 17 Aug 2021
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Aug 2021
Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials
Biopharmaceuticals Dermatology

HSMN NewsFeed - 1 Jun 2021
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 22 Apr 2021
Ortho Dermatologics Announces Statistically Significant Topline Results From Second Pivotal Phase 3 Clinical Trial Evaluating IDP-126 Gel In Acne Vulgaris
Biopharmaceuticals Dermatology

HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Biopharmaceuticals

HSMN NewsFeed - 8 Apr 2021
Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
Biopharmaceuticals

HSMN NewsFeed - 26 Jan 2021
Connect Biopharma Strengthens Leadership Team with Key Hire
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Dec 2020
New Dermatology Company Resilia Pharmaceuticals Begins Operations
Biopharmaceuticals Dermatology

HSMN NewsFeed - 11 Dec 2020
CHMP Recommends the Approvals of RINVOQ(TM) (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 18 Sep 2020
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 24 Aug 2020
Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 17 Jul 2020
Lilly's Mirikizumab Superior to Cosentyx(R) (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 23 Jun 2020
Ortho Dermatologics Launches ARAZLO(TM) (tazarotene) Lotion, 0.045%, In The United States
Biopharmaceuticals Dermatology Product Launch

HSMN NewsFeed - 19 Jun 2020
Dupixent(R) (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 18 May 2020
Hoth Therapeutics Procures Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatment
Biopharmaceuticals Dermatology Licensing

HSMN NewsFeed - 1 May 2020
SciBase Receives FDA Approval for Nevisense 3.0
Devices Dermatology Oncology FDA

HSMN NewsFeed - 17 Apr 2020
Hoth Therapeutics Announces Additions to its Board of Directors
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 20 Feb 2020
Lilly Completes Acquisition of Dermira
Biopharmaceuticals Dermatology Mergers & Acquisitions

HSMN NewsFeed - 10 Jan 2020
Lilly Announces Agreement to Acquire Dermira
Biopharmaceuticals Dermatology Mergers & Acquisitions

HSMN NewsFeed - 20 Dec 2019
Bausch Health Announces Resolution Of BRYHALI(R) (Halobetasol Propionate) Lotion, 0.01%, Intellectual Property Litigation With Glenmark
Biopharmaceuticals Dermatology Litigation

HSMN NewsFeed - 18 Oct 2019
AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ(TM)) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 3 Oct 2019
Turn Therapeutics(TM) Closes Series B Round to Fuel Lead Atopic Dermatitis Program Trial and Pipeline Expansion
Biopharmaceuticals Dermatology Venture Capital

HSMN NewsFeed - 2 Oct 2019
DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR(R) for the Treatment of Post-Surgical Pain
Biopharmaceuticals Drug Delivery Surgery FDA

HSMN NewsFeed - 6 Aug 2019
Dupixent(R) (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 27 Jun 2019
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 20 Jun 2019
DURECT Announces $15 Million Registered Direct Offering
Biopharmaceuticals Drug Delivery Venture Capital

HSMN NewsFeed - 7 May 2019
Dupixent(R) (dupilumab) Approved for Severe Asthma by European Commission
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Apr 2019
Aratana Therapeutics to be Acquired by Elanco Animal Health
Biopharmaceuticals Veterinary Mergers & Acquisitions

HSMN NewsFeed - 25 Apr 2019
DURECT Appoints Two New Board Members
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 13 Mar 2019
Hoth Therapeutics Enters into Commercial Licensing Agreement with University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc.
Biopharmaceuticals Dermatology Licensing

HSMN NewsFeed - 1 Mar 2019
CHMP Recommends Approval of Dupixent(R) (dupilumab) for Asthma Indication
Biopharmaceuticals Regulatory

HSMN NewsFeed - 19 Feb 2019
AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Dec 2018
Commercial Launch Plans Announced for PERSERIS(TM) (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
Biopharmaceuticals Product Launch

HSMN NewsFeed - 13 Dec 2018
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Oct 2018
FDA Approves Asthma Indication for Dupixent(R) (dupilumab)
Biopharmaceuticals FDA

HSMN NewsFeed - 8 Oct 2018
Bausch Health's BRYHALI(TM) (halobetasol propionate) Lotion, 0.01%, Receives Tentative FDA Approval For Plaque Psoriasis In Adults
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 12 Sep 2018
ExoCoBio Inc. raises $26.7M in Series B Funding
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 24 Aug 2018
Ortho Dermatologics Receives FDA Approval For ALTRENO(TM) (tretinoin 0.05%) Lotion For Acne
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 6 Aug 2018
AOBiome Therapeutics Announces the Expansion of its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Jun 2018
AOBiome Therapeutics Announces Election of Dr. Jun Wang as Chairman of the Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 May 2018
Positive Phase 3 Trial of DUPIXENT(R) (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 9 May 2018
DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR(R) (SABER(R)-Bupivacaine)
Biopharmaceuticals Drug Delivery Surgery Licensing

HSMN NewsFeed - 7 Mar 2018
Hoth Therapeutics Inc. Announces Completion of Series A Financing And Looks to Broaden Its Product Pipeline
Biopharmaceuticals Dermatology Venture Capital

HSMN NewsFeed - 2 Mar 2018
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Feb 2018
Hoth Therapeutics Inc. Announces Completion of Series A Financing
Biopharmaceuticals Dermatology Venture Capital

HSMN NewsFeed - 22 Jan 2018
Regeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 17 Oct 2017
Menlo Therapeutics Expands its Management Team
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 12 Oct 2017
Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ(TM) (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile
Biopharmaceuticals Dermatology

HSMN NewsFeed - 29 Sep 2017
Dermavant Sciences Appoints Vince Ippolito as President and Chief Operating Officer
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 28 Sep 2017
Regeneron and Sanofi Announce Approval of DUPIXENT(R) (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 27 Jul 2017
Valeant Announces U.S. Launch of SILIQ(TM) (brodalumab) Injection
Biopharmaceuticals Dermatology Product Launch

HSMN NewsFeed - 18 Jul 2017
Menlo Therapeutics Raises $50M
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 23 Jun 2017
LEO Pharma Appoints Chris Posner to Lead US Business
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 24 May 2017
Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 8 May 2017
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Apr 2017
Regeneron and Sanofi Announce Kevzara(R) (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Apr 2017
Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent(R) (alirocumab) Injection
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 24 Apr 2017
Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara(R) (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 14 Apr 2017
U.S. FDA Issues Complete Response Letter for Baricitinib
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Mar 2017
Sanofi and Regeneron Announce FDA Approval of Dupixent(R) (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 24 Mar 2017
Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 28 Feb 2017
Kevzara(TM) (sarilumab) now available in Canada for the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals Product Launch

HSMN NewsFeed - 14 Feb 2017
European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 9 Feb 2017
Appeals Court Grants Stay of Permanent Injunction for Praluent(R) (alirocumab) During Appeals Process
Biopharmaceuticals Cardiology Litigation

HSMN NewsFeed - 27 Jan 2017
Immune Pharmaceuticals Appoints New Chairman of the Board of Directors
Biopharmaceuticals Gastroenterology Oncology Personnel

HSMN NewsFeed - 6 Jan 2017
Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent(R) (alirocumab) Injection
Biopharmaceuticals Cardiology Litigation

HSMN NewsFeed - 4 Jan 2017
Regeneron Hires Jay Markowitz, M.D., as Senior Vice President of Portfolio Management
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Dec 2016
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Dec 2016
Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent(R) (dupilumab) Accepted for Review by the EMA
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 17 Nov 2016
Regeneron and Sanofi Announce Praluent(R) (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis
Biopharmaceuticals

HSMN NewsFeed - 25 Oct 2016
Allergan Successfully Completes Vitae Tender Offer
Biopharmaceuticals Dermatology Mergers & Acquisitions

HSMN NewsFeed - 17 Oct 2016
Allergan and Vitae Pharmaceuticals Announce Expiration of HSR Waiting Period for Allergan's Proposed Acquisition of Vitae
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 26 Sep 2016
Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 14 Sep 2016
DS Biopharma Announces the Appointment of Dr. Markus Weissbach as Chief Operating Officer
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 12 Sep 2016
Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Aug 2016
Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent(R) (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
Biopharmaceuticals Cardiology

HSMN NewsFeed - 5 Jul 2016
Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 24 Jun 2016
Pfizer Completes Acquisition of Anacor
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 6 Jun 2016
Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 16 May 2016
Pfizer to Acquire Anacor
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 1 Apr 2016
Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Biopharmaceuticals Dermatology

HSMN NewsFeed - 11 Mar 2016
Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 29 Feb 2016
Genentech Provides Update On Two Identical Phase III Studies Of Lebrikizumab In People With Severe Asthma
Biopharmaceuticals

HSMN NewsFeed - 30 Oct 2015
Regeneron Announces EU Approval of EYLEA(R) (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 28 Sep 2015
Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in the European Union
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 3 Sep 2015
Atopix Therapeutics Appoints Dr Andrew Zambanini as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Jul 2015
Regeneron and Sanofi Announce FDA Approval of Praluent(R) (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 24 Jul 2015
Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia
Biopharmaceuticals Regulatory

HSMN NewsFeed - 2 Jul 2015
Provectus Biopharmaceuticals Signs Letter of Intent with Boehringer Ingelheim (China) to Collaborate in Bringing PV-10 to Market in China
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 26 Jun 2015
EYLEA(R) (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 21 May 2015
Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 8 May 2015
Provectus Biopharmaceuticals Updates Market on Business Developments
Biopharmaceuticals Dermatology Oncology

HSMN NewsFeed - 26 Feb 2015
EYLEA(R) (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 26 Jan 2015
Regeneron and Sanofi Announce Praluent(TM) (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Oct 2014
EYLEA(R) (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 22 Sep 2014
Regeneron Announces EYLEA(R) (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 11 Aug 2014
EYLEA(R) (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 21 Jul 2014
Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of KERYDIN in the United States
Biopharmaceuticals Dermatology Distribution

HSMN NewsFeed - 27 Jun 2014
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 21 May 2014
Provectus Biopharmaceuticals Inc. Appoints Jacob M. Plotsker to Strategic Advisory Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Feb 2014
Two-Year Results From Phase 3 VISTA Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 4 Feb 2014
Oculus Innovative Sciences Receives European CE Mark for Use of Microcyn(R) in the Topical Treatment of Mild to Moderate Acne
Devices Dermatology Regulatory

HSMN NewsFeed - 3 Feb 2014
Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million
Biopharmaceuticals Dermatology Mergers & Acquisitions

HSMN NewsFeed - 18 Dec 2013
Regeneron Announces FDA Acceptance of EYLEA(R) (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 17 Dec 2013
Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware
Biopharmaceuticals Dermatology Oncology

HSMN NewsFeed - 22 Nov 2013
EYLEA(R) (aflibercept) Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 22 Nov 2013
Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Biopharmaceuticals

HSMN NewsFeed - 24 Oct 2013
Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Jul 2013
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 15 May 2013
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
Biopharmaceuticals

HSMN NewsFeed - 26 Feb 2013
Brickell Biotech Announces $7M Series B Financing to Fund Development of Novel Dermatology Treatments
Biopharmaceuticals Dermatology Venture Capital

HSMN NewsFeed - 5 Feb 2013
ZALTRAP(R) (ziv-aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 3 May 2012
Creabilis Appoints Dr Simon Russell as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Oct 2011
Panmira Announces Appointment of New CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Oct 2011
Creabilis Raises 15M ($20M) in Series B Fundraising Round
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 18 Aug 2011
Creabilis Expands Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Aug 2011
Creabilis Appoints Dr David Roblin as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Apr 2011
Meda to License Elidel to Valeant Pharmaceuticals
Biopharmaceuticals Licensing

HSMN NewsFeed - 4 Apr 2011
Anacor Pharmaceuticals Appoints William J. Rieflin to Its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Feb 2011
Circassia Acquires Worldwide Rights to Novel Psoriasis and Atopic Dermatitis Treatment From Airmid Inc
Biopharmaceuticals Dermatology Acquisitions

HSMN NewsFeed - 8 Feb 2011
Oculus Innovative Sciences Receives New FDA 510(k) Clearance for Microcyn-Based Dermatology HydroGel for Management of Atopic Dermatitis, Radiation Dermatitis and Other Skin Dermatoses
Devices Dermatology FDA

HSMN NewsFeed - 10 Jan 2011
KYTHERA and Intendis Announce Initiation of European Phase III Clinical Development Program to Evaluate ATX-101 for Reduction of Submental Fat
Biopharmaceuticals Dermatology

HSMN NewsFeed - 11 Nov 2010
Arbor Pharmaceuticals Completes $34.8 Million Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 27 Oct 2010
Laurence J. Downey, MD Joins Arbor Pharmaceuticals as Vice President of Medical Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Oct 2010
Anacor Pharmaceuticals Appoints Geoffrey M. Parker as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Sep 2010
Bristol-Myers Squibb to Acquire ZymoGenetics
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 15 Jul 2010
Provectus Pharmaceuticals Reports Achieved Milestones for First Half of 2010, Recent Developments and Plans for the Remainder of the Year to Shareholders
Biopharmaceuticals Dermatology Oncology

HSMN NewsFeed - 27 Jan 2010
Onset Therapeutics Announces Expansion in the Dermatology Market
Biopharmaceuticals Dermatology

HSMN NewsFeed - 27 Jul 2009
Ceragenix and MEGAPHARM Enter Into Distribution and Supply Agreement for EpiCeram(R)
Biopharmaceuticals Dermatology Distribution

HSMN NewsFeed - 9 Feb 2009
Aerovance Appoints Babatunde A. Otulana, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Jan 2009
Protopic(R) Ointment (tacrolimus monohydrate) Receives Positive Opinion for Twice-Weekly use (Maintenance Treatment) in the Treatment of Atopic Dermatitis by the European Medicines Agency
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 14 Oct 2008
Dr. Reddy's Wholly-Owned Subsidiary Promius Pharma Launches EPICERAM(R) Skin Barrier Emulsion
Biopharmaceuticals Dermatology

HSMN NewsFeed - 14 Oct 2008
Promius Pharma, LLC Launches EpiCeram(R) Skin Barrier Emulsion
Biopharmaceuticals Dermatology

HSMN NewsFeed - 18 Sep 2008
Dr. Reddy's Formally Announces its US Specialty Business, Promius Pharma, LLC.
Biopharmaceuticals Dermatology

HSMN NewsFeed - 10 Sep 2008
VioQuest Pharmaceuticals Receives 510(k) Response from FDA for Xyfid(TM)
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 13 May 2008
PhotoMedex Receives FDA Clearance for the XTRAC(R) Velocity(TM) Laser
Devices Dermatology FDA

HSMN NewsFeed - 13 May 2008
Skinvisible Signs Licensing Agreement for Two Acne Formulations
Biopharmaceuticals Dermatology Licensing

HSMN NewsFeed - 28 Apr 2008
Nuon Therapeutics Inc. Completes $27 Million Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 25 Mar 2008
Ceragenix Enters into Agreement to License CSA-54 and other Ceragenin Compounds To Biopharmaceutical Company for HIV and STD Applications
Biopharmaceuticals HIV/AIDS Licensing

HSMN NewsFeed - 18 Mar 2008
CeraShield(TM) Coated Endotracheal Tubes Provide up to 21 Days of Protection against Bacterial Colonization in Preclinical Testing
Devices

HSMN NewsFeed - 14 Mar 2008
Biologics, Dermal Fillers are Key to Dermatological Drug Market Growth
Devices Biopharmaceuticals Dermatology

HSMN NewsFeed - 27 Feb 2008
Manhattan Pharmaceuticals Announces Closing of Joint Venture With Nordic Biotech
Biopharmaceuticals

HSMN NewsFeed - 3 Feb 2008
American Academy of Dermatology Research Confirms Genetic Skin Barrier Defect Linked to Eczema
Dermatology

HSMN NewsFeed - 27 Dec 2007
Manhattan Pharmaceuticals Names Mary C. Spellman, M.D. as Head of Dermatology and Drug Development
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 19 Nov 2007
Meyer Pharmaceuticals Acquires NF-kappaB Decoy Technology for Treatment of Inflammatory Disease
Biopharmaceuticals Dermatology Licensing

HSMN NewsFeed - 19 Nov 2007
Ceragenix and Dr. Reddy's Enter Into Distribution and Supply Agreement for EpiCeram(R)
Biopharmaceuticals Dermatology Distribution

HSMN NewsFeed - 18 Sep 2007
PhotoMedex Hires Paul TanPiengco as Director of Marketing
Devices Personnel

HSMN NewsFeed - 10 Jul 2007
Manhattan Pharmaceuticals Provides Update on Clinical Pipeline
Biopharmaceuticals

HSMN NewsFeed - 12 Jun 2007
FDA Grants Ceragenix's Request for Designation
Devices Biopharmaceuticals Wound Care FDA

HSMN NewsFeed - 25 Apr 2007
Ceragenix Commences Second in Series of Clinical Trials
Biopharmaceuticals Dermatology

HSMN NewsFeed - 24 Apr 2007
Ceragenix Announces Results from Phase IV Study of EpiCeram(TM) Meet All Primary and Secondary Endpoints
Biopharmaceuticals Dermatology

HSMN NewsFeed - 24 Apr 2007
New TNS(R) Serum From SkinMedica(R) Exclusively Applied Through HydraFacial MD(TM) by Edge Systems
Biopharmaceuticals Dermatology

HSMN NewsFeed - 2 Feb 2007
Anacor Signs Worldwide Exclusive License Agreement With Schering-Plough for AN2690, a New Topical Anti-Fungal Treatment
Biopharmaceuticals Licensing

HSMN NewsFeed - 23 Jan 2007
Stiefel Laboratories Receives FDA Approval of Olux-E (Clobetasol Propionate) Foam, 0.05% for Treatment of Psoriasis and Eczema
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 8 Jan 2007
SkinMedica Launches NeoBenz(R) Micro SD for Acne
Biopharmaceuticals Dermatology Drug Delivery

HSMN NewsFeed - 18 Dec 2006
Plymouth Pharmaceuticals(R) Launches New Drug, Eczemol(R), for Pediatricians, Dermatologists, and Family Practitioners
Biopharmaceuticals Dermatology

HSMN NewsFeed - 9 Nov 2006
3M Reaches Agreements to Sell its Pharmaceuticals Business
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 9 Nov 2006
Graceway Pharmaceuticals to Acquire 3M Pharmaceuticals Business in North and Latin America
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 9 Nov 2006
GTCR Announces Graceway Pharmaceuticals' Agreement to Acquire 3M's Pharmaceutical Business in North and Latin America
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 7 Nov 2006
SkinMedica and Galderma to Co-Promote Desonate(TM)
Biopharmaceuticals Dermatology

HSMN NewsFeed - 23 Oct 2006
SkinMedica(R) Announces FDA Approval of Desonate(TM) (Desonide) Gel 0.05% With Patented Hydrogel Technology for Treatment of Atopic Dermatitis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 23 Oct 2006
Connetics Corporation and Stiefel Laboratories, Inc. Sign Definitive Merger Agreement
Biopharmaceuticals Mergers & Acquisitions Dermatology

HSMN NewsFeed - 23 Oct 2006
Connetics Corporation to Merge into Stiefel Laboratories
Biopharmaceuticals Mergers & Acquisitions Dermatology

HSMN NewsFeed - 19 Sep 2006
FDA Approves Connetics' Verdeso Foam for the Treatment of Mild-to-Moderate Atopic Dermatitis
Biopharmaceuticals Dermatology Drug Delivery FDA

HSMN NewsFeed - 18 Sep 2006
Anacor Expands Clinical Development Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jun 2006
Connetics Names Cynthia Canup Director, Sales Training
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 May 2006
Connetics Names Sunil Patel Vice President, Corporate Development and Strategy
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 May 2006
Aerovance Secures $60 Million in Financing
Biopharmaceuticals Venture Capital

Return to NewsFeed

Additional items found! 72

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 72 additional stories matching:
Atopic Dermatitis
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!